Opdivo In Focus After BMY's Checkmate-214 Study Being Stopped Early

Bristol-Myers Squibb's oncology business accounts for over 60% of the company valuation, according to our estimates. The performance of pharmaceutical stocks is highly tied to clinical trial results, and for BMY the uptake of its new cancer drugs, especially Opdivo, is of key importance.